FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals

If your email program has trouble displaying this email, view as a webpage. FDA Office of Minority Health and Health Equity   FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals Other fully vaccinated individuals do not need an additional vaccine dose right now The U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is scheduled to meet Friday to discuss further clinical recommendations regarding immunocompromised individuals. This action does not apply to people who are not immunocompromised.  Read FDA News Release   Visit the FDA OMHHE website and follow us on Twitter at @FDAHealthEquity  "Creating a world where health equity is a reality for all." www.fda.gov/HealthEquity

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA